{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-10",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "submissions": [
        {
          "submission_type": "SUPPL",
          "submission_number": "2",
          "submission_status": "AP",
          "submission_status_date": "20210408",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "67011",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212295Orig1s002ltr.pdf",
              "date": "20210409",
              "type": "Letter"
            },
            {
              "id": "67024",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212295s002lbl.pdf",
              "date": "20210412",
              "type": "Label"
            }
          ]
        },
        {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20200702",
          "submission_public_notes": "FR Notice on DEA Scheduling; Date of Approval  October 6, 2020",
          "review_priority": "STANDARD",
          "submission_class_code": "TYPE 1",
          "submission_class_code_description": "Type 1 - New Molecular Entity",
          "application_docs": [
            {
              "id": "63788",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf",
              "date": "20200702",
              "type": "Label"
            },
            {
              "id": "63794",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212295Orig1s000ltr.pdf",
              "date": "20200706",
              "type": "Letter"
            },
            {
              "id": "64155",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000TOC.html",
              "date": "20200731",
              "type": "Review"
            },
            {
              "id": "68930",
              "url": "https://www.federalregister.gov/documents/2020/10/06/2020-19313/schedules-of-controlled-substances-placement-of-remimazolam-in-schedule-iv",
              "date": "20211008",
              "type": "Federal Register Notice"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "3",
          "submission_status": "AP",
          "submission_status_date": "20230113",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "73216",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212295s003lbl.pdf",
              "date": "20230117",
              "type": "Label"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20201130",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "65440",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212295Orig1s001ltr.pdf",
              "date": "20201201",
              "type": "Letter"
            },
            {
              "id": "65450",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s001lbl.pdf",
              "date": "20201201",
              "type": "Label"
            }
          ]
        }
      ],
      "application_number": "NDA212295",
      "sponsor_name": "ACACIA",
      "openfda": {
        "application_number": [
          "NDA212295"
        ],
        "brand_name": [
          "BYFAVO"
        ],
        "generic_name": [
          "REMIMAZOLAM BESYLATE"
        ],
        "manufacturer_name": [
          "Acacia Pharma, Ltd."
        ],
        "product_ndc": [
          "71390-011"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "INTRAVENOUS"
        ],
        "substance_name": [
          "REMIMAZOLAM BESYLATE"
        ],
        "rxcui": [
          "2383946",
          "2383951"
        ],
        "spl_id": [
          "4da618a9-2e04-4d75-922b-173d22b4e84c"
        ],
        "spl_set_id": [
          "4e1838f2-b999-41a7-a761-d94f09aa531f"
        ],
        "package_ndc": [
          "71390-011-00",
          "71390-011-11"
        ],
        "unii": [
          "280XQ6482H"
        ]
      },
      "products": [
        {
          "product_number": "001",
          "reference_drug": "Yes",
          "brand_name": "BYFAVO",
          "active_ingredients": [
            {
              "name": "REMIMAZOLAM BESYLATE",
              "strength": "EQ 20MG BASE/VIAL"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "POWDER",
          "route": "INTRAVENOUS",
          "marketing_status": "Prescription"
        }
      ]
    }
  ]
}